Ad
related to: is blinatumomab chemotherapy
Search results
Results from the WOW.Com Content Network
Blinatumomab, sold under the brand name Blincyto, and known informally as blina, [5] is a biopharmaceutical medication used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia.
Blinatumomab links T cells with CD19 receptors found on the surface of B cells. The Food and Drug Administration (US) and the European Medicines Agency approved this therapy for adults with Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia.
However, this subtype of ALL is frequently resistant to the combination of chemotherapy and TKIs and allogeneic stem cell transplantation is often recommended upon relapse. [54] Blinatumomab is not only a promising add-on to chemotherapy in infant ALL, [56] it is also a promising standalone therapy in children's. [57]
The princess said she was undergoing ‘preventative chemotherapy’ after revealing she had been diagnosed with cancer. Skip to main content. 24/7 Help. For premium support please call: 800-290 ...
Blinatumomab: Treatment of CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy in people aged one month of age and older [2] Budesonide: For twelve weeks of treatment in people aged eleven years of age and older with eosinophilic esophagitis [2]
A growing shortage of common cancer treatments is forcing doctors to switch medications and delaying some care, prominent U.S. cancer centers say. The National Comprehensive Cancer Network said ...
Brentuximab vedotin [6] consists of the chimeric monoclonal antibody brentuximab (cAC10, which targets the cell-membrane protein CD30) linked with maleimide attachment groups, cathepsin-cleavable linkers (valine-citrulline), and para-aminobenzylcarbamate spacers to three to five units of the antimitotic agent monomethyl auristatin E (MMAE, reflected by the 'vedotin' in the drug's name). [7]
The benefit and side effects of loncastuximab tesirine were evaluated in one clinical trial, ADCT-402-201 (LOTIS-2 / NCT03589469), that included 145 participants with relapsed or refractory diffuse large B-cell lymphoma after at least two prior treatments that did not work or were no longer working.
Ad
related to: is blinatumomab chemotherapy